In a landmark achievement for the European biotechnology sector, Naarden-based venture capital firm Forbion has announced the successful closing of two new funds totaling €2.3 billion (approximately $2.6 billion). This capital raise represents the largest in the firm’s 20-year history and solidifies its position as the continent’s largest dedicated life sciences investment house. The move comes at a critical juncture for the global venture capital (VC) landscape, which has been characterized by a stark geographic imbalance and a narrowing of capital flow toward established, high-performing entities.
The total amount was raised across two distinct vehicles: Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. With these additions, Forbion now oversees approximately €7.5 billion ($8.5 billion) in assets under management (AUM) across 13 funds. The firm’s ability to secure such significant commitments reflects a "flight to quality" among institutional investors who are increasingly selective in a market still recovering from the liquidity constraints of the mid-2020s.
Strategic Allocation and Fund Structure
The dual-fund strategy employed by Forbion is designed to cover the entire lifecycle of biotech innovation. Forbion Ventures Fund VIII is slated to focus on early-stage opportunities, targeting the creation of new companies built around novel scientific discoveries and supporting them through the proof-of-concept stage. Conversely, Forbion Growth Opportunities Fund IV is engineered to provide late-stage capital, helping mature biotech firms scale their operations, navigate pivotal clinical trials, and prepare for public listings or acquisitions.
According to the firm’s internal projections, the new capital is expected to support a portfolio of approximately 30 companies. By spanning both early-stage venture and late-stage growth, Forbion aims to mitigate the "valley of death"—the funding gap that often occurs between initial laboratory success and the expensive clinical trials required for regulatory approval.
Sander Slootweg, Forbion’s co-founder and Managing Partner, emphasized that the scale of this fundraise allows the firm to take more significant stakes in "paradigm-shifting" treatments. The firm’s investment philosophy remains rooted in addressing high unmet medical needs while delivering both societal impact and robust financial returns for its limited partners.
Comparative Analysis of the Global VC Landscape
The success of Forbion’s fundraising efforts stands in sharp contrast to the broader trends observed in the European venture market. According to recent data from Pitchbook through the third quarter of 2026, global VC fundraising is on a trajectory to exceed $200 billion for the full year. While this suggests a recovery from the lows of 2025, the data reveals a troubling concentration of capital.
A significant majority—roughly two-thirds—of all financial commitments in 2026 have been directed toward firms based in North America. In contrast, Europe is currently on track for its lowest fundraising total since 2019, excluding the anomaly of the previous year. This "geographic decoupling" suggests that while American firms are benefiting from a revitalized appetite for risk, European managers are facing a much tougher environment for securing new commitments.
Furthermore, the Pitchbook report highlights that more money is flowing into fewer funds. Large, established players like Forbion are successfully attracting mega-allocations, while smaller, first-time, or specialized funds struggle to reach their targets. This consolidation of "dry powder" into the hands of a few major firms is reshaping the competitive landscape of the life sciences sector, as it limits the number of gatekeepers who decide which medical technologies receive the funding necessary to reach the market.
A Chronology of Recent Investment Activity
Forbion has not waited for the final closing of these funds to begin deploying capital. The firm has already executed several high-profile investments that signal its current strategic priorities.
In early 2026, Forbion participated in the $130 million Series A financing of Slate Medicines, a North Carolina-based developer focused on migraine treatments. Slate Medicines has since moved toward a reverse merger to enter the public markets, a common exit strategy in the current economic climate where traditional Initial Public Offerings (IPOs) remain selective.
In the second quarter of 2026, Forbion led the $125 million Series A for Coultreon Biopharma. Based in Belgium, Coultreon is developing a SIK inhibitor (salt-inducible kinase) initially licensed from Galapagos. This investment highlights Forbion’s commitment to the European immunology space and its strategy of "company building"—taking promising assets from larger pharmaceutical companies and spinning them out into focused, agile startups.
The firm’s investment history over the past two decades has been marked by several notable exits and clinical successes, which provided the track record necessary to attract the current round of funding. By consistently backing platforms that result in M&A activity with big pharma, Forbion has maintained a liquidity profile that appeals to large institutional investors.
Investor Composition and Institutional Support
The €2.3 billion raise was supported by a diverse group of limited partners, ranging from sovereign wealth funds and pension managers to strategic corporate investors. Disclosed participants include:
- MN and PGGM: Major Dutch pension providers that have historically supported domestic innovation.
- KfW Capital: The investment arm of the German state-owned development bank, reflecting Forbion’s influence in the DACH region.
- Kauffman Foundation: A prominent U.S.-based private foundation focused on entrepreneurship.
- Eli Lilly and Company: The American pharmaceutical giant’s participation as a strategic investor is particularly noteworthy.
The involvement of Eli Lilly underscores a growing trend of "corporate-VC synergy." For big pharma, investing in funds like Forbion provides a front-row seat to the most promising early-stage research, potentially serving as a pipeline for future acquisitions. For Forbion, having a partner like Lilly provides not only capital but also a layer of validation and potential technical expertise for its portfolio companies.
Implications for the European Biotech Ecosystem
The influx of €2.3 billion into the European life sciences sector is expected to have a stabilizing effect on the regional ecosystem. Historically, European biotech has suffered from a lack of late-stage "scale-up" capital, often forcing promising companies to relocate to the United States or seek listings on the NASDAQ prematurely.
With Forbion Growth Opportunities Fund IV, there is now a substantial pool of domestic capital available to keep these companies in Europe longer. This helps retain high-value scientific talent and intellectual property within the European Union and the UK. However, analysts suggest that while Forbion’s raise is a positive sign, it may not be enough to bridge the total funding gap between the U.S. and Europe.
The Pitchbook data indicates that deal counts are declining in every global region except North America. This suggests that while the "value" of deals might be high (driven by mega-rounds like those led by Forbion), the "breadth" of the market is narrowing. Early-stage startups that do not immediately show "paradigm-shifting" potential may find it increasingly difficult to secure seed and Series A funding as VCs prioritize their "winners" and late-stage bets.
Future Outlook and Societal Impact
As Forbion begins to deploy this new capital, the focus will likely remain on therapeutic areas with the highest unmet needs: oncology, immunology, and rare genetic disorders. The firm has also shown increasing interest in "platform technologies"—methods of drug delivery or discovery that can be applied to multiple diseases rather than a single candidate.
The broader implications for healthcare are significant. The $2.6 billion in new funding will directly finance the clinical trials of dozens of new drugs. If successful, these therapies could provide new options for patients with chronic conditions that currently have limited treatment pathways.
In the coming months, the industry will be watching to see if other European VC firms can replicate Forbion’s fundraising success. If Forbion remains an outlier, it may signal a permanent shift toward a "winner-take-all" dynamic in the European venture market. However, if this raise marks the beginning of a broader trend, it could herald a new era of growth for European biotechnology, characterized by larger funds, longer investment horizons, and a more robust pipeline of home-grown medical innovation.
For now, Forbion’s €2.3 billion milestone serves as a testament to the resilience of the life sciences sector. Even in a market plagued by geographic imbalances and liquidity concerns, the demand for breakthrough medical solutions continues to attract significant financial commitment from the world’s most sophisticated investors.
